The role of persistent gastrointestinal viral infections in the development of enteropathy in children with Common Variable Immunodeficiency and secundary immunodeficiencies

The role of persistent gastrointestinal viral infections in the development of enteropathy in children with Common Variable Immunodeficiency and secundary immunodeficiencies - Chronic gastrointestinal viruses in immunocompromised children

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39272

Enrollment

155

Registered

2009-05-12

Start date

2010-04-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

defective antibody production of unknown cause primary immunodeficiency

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: CVID: diagnosed according to the ESID criteria: Normal to low numbers of B lymphocytes. Impaired specific antibody production after immunisation (less than 4-fold titer increase after polysaccharide vaccination) Low (

Exclusion criteria

Exclusion criteria: For all patient groups: a proven primary immunodeficiency other than CVID, e.g. X-linked agammaglobulinemia (XLA) or hyper-IgM syndrome (HIGM), or a strong suspicion of one of these diseases. For the healthy controls and SCT patients: immune disease, pre-existent gastrointestinal tract disease (e.g. Morbus Crohn, celiac disease, ulcerative colitis)

Design outcomes

Primary

Measure	Time frame
1. The prevalence of enteropathogenic virus infections in children and adolescents with CVID(-like disease) and SCT patients 2. An association between viral excretion and auto-/allo-immune enteropathy	—

Secondary

Measure	Time frame
1. The prevalence of symptomatic and asymptomatic enteropathogenic viral infections in CVID(-like disease) 2. If any viruses are found: to assess a. Duration of infection b. Specification of the pathogen c. Association between pathogen and clinical findings of the patient 3. To explore the potential differences in prevalence between the pediatric CVID population, 'CVID-like disease' population and healthy children/adolescents.	—

Measure

Time frame

1. The prevalence of symptomatic and asymptomatic enteropathogenic viral infections in CVID(-like disease) 2. If any viruses are found: to assess a. Duration of infection b. Specification of the pathogen c. Association between pathogen and clinical findings of the patient 3. To explore the potential differences in prevalence between the pediatric CVID population, 'CVID-like disease' population and healthy children/adolescents.

—

Countries

Netherlands

Outcome results